Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours [5]

British Journal of Dermatology

Volumn 151, Issue 1, 2004, Pages 238-241

  Jacot, W ^a   Bessis, D ^b   Jorda, E ^c   Ychou, M ^d   Fabbro, M ^d   Pujol, J L ^a   Guillot, B ^b  

^a Montpellier Academic Hospital   (France)

^b HÔPITAL SAINT ELOI   (France)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CETUXIMAB; CORTICOSTEROID; ECONAZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROMYCIN; FUSIDIC ACID; GEFITINIB; HEXAMIDINE; IMC C 225; LYMECYCLINE; PENICILLIN G; POVIDONE IODINE;

ACNE; ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLICULITIS; HISTOLOGY; HUMAN; LETTER; MALE; PAPULE; PRIORITY JOURNAL; PUSTULE; RASH; SOLID TUMOR;

ACNEIFORM ERUPTIONS; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 4043133757     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06026.x     Document Type: Letter

References (10)

1. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1-13S.
2. Culy CR, Faulds D. Gefitinib. Drugs 2002; 62: 2237-48, discussion 2249-50.
3. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-50.
4. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76.
5. van Doorn R, Kirtschig G, Scheffer E et al. Follicular epidermal alterations patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601.
6. Plewig G, Jansen T. Acneiform dermatoses. Dermatology 1998; 196; 102-7.
7. Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14: 922-30.
8. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7.
9. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
10. Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 99-101.